Stay updated on Nivolumab vs Combo Immunotherapy in Non-Clear Cell RCC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab vs Combo Immunotherapy in Non-Clear Cell RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab vs Combo Immunotherapy in Non-Clear Cell RCC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents the number of participants expected to participate in a study evaluating new treatments for kidney cancer using Nivolumab and Ipilimumab.
    Difference
    0.1%
    Check dated 2024-06-06T14:21:44.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for participants, including specific health conditions and prior treatments required for inclusion in the study. Previously, this section had no information provided.
    Difference
    42%
    Check dated 2024-05-22T20:31:10.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Summary
    The value 'Go to the classic website Go to the classic website 5 2' on the webpage has been updated to 'Site Map 6 0'. This change possibly indicates a shift in the type of intervention related to medical and healthcare publications and documentation.
    Difference
    0.7%
    Check dated 2024-05-01T21:55:20.000Z thumbnail image

Stay in the know with updates to Nivolumab vs Combo Immunotherapy in Non-Clear Cell RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Combo Immunotherapy in Non-Clear Cell RCC Clinical Trial page.